Skip to main content
. Author manuscript; available in PMC: 2018 May 23.
Published in final edited form as: J Endocrinol Diabetes. 2017 Oct 4;4(4):10.15226/2374-6890/4/4/00184. doi: 10.15226/2374-6890/4/4/00184

Table 4.

Effect of antagonists of the PLC/IP3R/Ca2+ pathway on autoantibody- induced N2ANeurite retraction

Treatment [Conc] % Diab Autoantibody-induced
neurite retraction*
Diabetic autoantibody 50 nM 100 ±0 %
Y27632 10 µM −12±3%
U73122 (PLC inhibitor) 1 µM 12 ± 4 %
BAPTA-AM (Ca2+ chelator) 30 µM 0 ± 0 %
2-APB (IP3R inhibitor) 50 µM −14±7%
*

Neurite retraction was determined as percent of acute neurite shortening (after 25 mins Exposure) in the presence of 50 nM diabetic autoantibodies alone, or following a brief pre incubation (10 mins) with indicated concentrations of specific antagonists of the PLC/IP3/Ca2+ path way or RhoA/ROCK signaling pathway. Results are mean ± SD in two or more experiments.